Surmodics (SRDX) Competitors $33.39 -0.64 (-1.88%) Closing price 04:00 PM EasternExtended Trading$33.39 0.00 (0.00%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRDX vs. ATRC, IART, OFIX, ANGO, ARAY, RMTI, RSLS, ABT, ISRG, and BSXShould you be buying Surmodics stock or one of its competitors? The main competitors of Surmodics include AtriCure (ATRC), Integra LifeSciences (IART), Orthofix Medical (OFIX), AngioDynamics (ANGO), Accuray (ARAY), Rockwell Medical (RMTI), ReShape Lifesciences (RSLS), Abbott Laboratories (ABT), Intuitive Surgical (ISRG), and Boston Scientific (BSX). These companies are all part of the "health care equipment" industry. Surmodics vs. Its Competitors AtriCure Integra LifeSciences Orthofix Medical AngioDynamics Accuray Rockwell Medical ReShape Lifesciences Abbott Laboratories Intuitive Surgical Boston Scientific AtriCure (NASDAQ:ATRC) and Surmodics (NASDAQ:SRDX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability. Which has more risk and volatility, ATRC or SRDX? AtriCure has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Surmodics has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500. Is ATRC or SRDX more profitable? AtriCure has a net margin of -7.27% compared to Surmodics' net margin of -14.59%. Surmodics' return on equity of -2.99% beat AtriCure's return on equity.Company Net Margins Return on Equity Return on Assets AtriCure-7.27% -4.20% -3.19% Surmodics -14.59%-2.99%-1.99% Does the media prefer ATRC or SRDX? In the previous week, AtriCure and AtriCure both had 8 articles in the media. AtriCure's average media sentiment score of 1.74 beat Surmodics' score of 1.71 indicating that AtriCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AtriCure 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Surmodics 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do insiders and institutionals believe in ATRC or SRDX? 99.1% of AtriCure shares are held by institutional investors. Comparatively, 96.6% of Surmodics shares are held by institutional investors. 3.5% of AtriCure shares are held by company insiders. Comparatively, 8.9% of Surmodics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has higher valuation & earnings, ATRC or SRDX? Surmodics has lower revenue, but higher earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtriCure$465.31M3.81-$44.70M-$0.77-46.31Surmodics$126.08M3.79-$11.54M-$1.23-27.15 Do analysts recommend ATRC or SRDX? AtriCure currently has a consensus price target of $50.89, indicating a potential upside of 42.71%. Surmodics has a consensus price target of $43.00, indicating a potential upside of 28.78%. Given AtriCure's stronger consensus rating and higher possible upside, equities analysts plainly believe AtriCure is more favorable than Surmodics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AtriCure 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Surmodics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 SummaryAtriCure beats Surmodics on 10 of the 15 factors compared between the two stocks. Get Surmodics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRDX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRDX vs. The Competition Export to ExcelMetricSurmodicsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$486.55M$10.94B$5.76B$9.85BDividend YieldN/A1.85%6.71%4.51%P/E Ratio-27.1514.7559.1122.53Price / Sales3.7931.25547.00119.09Price / Cash109.9924.5637.0558.92Price / Book4.013.5710.916.06Net Income-$11.54M$212.34M$3.29B$266.28M7 Day Performance-2.74%-3.31%0.01%-0.76%1 Month Performance-6.29%7.76%7.06%3.83%1 Year Performance-13.97%-8.09%50.09%24.39% Surmodics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRDXSurmodics4.4604 of 5 stars$33.39-1.9%$43.00+28.8%-13.2%$486.55M$126.08M-27.15450Positive NewsATRCAtriCure3.7712 of 5 stars$36.99-0.6%$50.89+37.6%+34.0%$1.84B$465.31M-48.041,300News CoveragePositive NewsIARTIntegra LifeSciences3.4998 of 5 stars$15.13+2.0%$18.43+21.8%-21.5%$1.18B$1.61B-2.324,396News CoveragePositive NewsOFIXOrthofix Medical3.3519 of 5 stars$14.98+1.6%$21.50+43.5%-11.8%$591.62M$799.49M-4.731,616News CoveragePositive NewsANGOAngioDynamics4.2843 of 5 stars$10.26+1.3%$19.00+85.2%+45.1%$416.90M$292.50M-12.36760Positive NewsARAYAccuray4.6839 of 5 stars$1.52-2.6%$5.00+228.9%-30.8%$171.27M$458.51M-76.001,040News CoverageRMTIRockwell Medical3.8649 of 5 stars$1.71-5.0%$4.00+133.9%-46.6%$58.88M$101.49M-28.50300Short Interest ↑High Trading VolumeRSLSReShape Lifesciences0.0159 of 5 stars$3.16-1.4%N/A-99.6%$8.49M$8.01M-0.0350Gap DownHigh Trading VolumeABTAbbott Laboratories4.9355 of 5 stars$132.59+0.9%$144.47+9.0%+15.1%$230.89B$41.95B16.61114,000Positive NewsISRGIntuitive Surgical4.9696 of 5 stars$473.30-0.1%$595.95+25.9%-8.7%$169.67B$8.35B66.0115,638Positive NewsInsider TradeBSXBoston Scientific4.4369 of 5 stars$105.56-0.2%$117.50+11.3%+32.3%$156.32B$16.75B62.8353,000Positive NewsInsider Trade Related Companies and Tools Related Companies AtriCure Competitors Integra LifeSciences Competitors Orthofix Medical Competitors AngioDynamics Competitors Accuray Competitors Rockwell Medical Competitors ReShape Lifesciences Competitors Abbott Laboratories Competitors Intuitive Surgical Competitors Boston Scientific Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRDX) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surmodics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Surmodics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
